Author: therawinformant

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

On Wednesday morning, Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) presented new data from a final efficacy analysis on their BNT162b2 vaccine candidate, and the news was very good.

In a joint press release, the 2 partners said the vaccine met all of its primary efficacy endpoints. Better still, it had an efficacy rate of 95% in participants both with and without prior coronavirus infection (mild or severe). Also, the vaccine’s efficacy was consistent across key demographics such as age, gender, and ethnicity. No serious safety concerns were reported.

That rate, meanwhile, is higher than the 90%-plus demonstrated in the interim analysis of trial data published last week by Pfizer and BioNTech.

With this fresh data, the two companies can now submit BNT162b2 to the United States Food and Drug Administration for emergency use authorisation (EUA), which Pfizer said they planned to do “within days”. The vaccine would be cleared for use with an EUA.

“Our objective from the very beginning was to design and develop a vaccine that would generate rapid and potent protection against COVID-19 with a benign tolerability profile across all ages,” BioNTech CEO Ugur Sahin was quoted as saying.

“We believe we have achieved this with our vaccine candidate BNT162b2 in all age groups studied so far, and look forward to sharing further details with the regulatory authorities.”

The 2 companies say they expect to be able to produce up to 50 million doses of their vaccine by the end of this year, and as many as 1.3 billion by the close of 2021.

Both Pfizer and BioNTech’s stocks were on the rise in late-morning US trading Wednesday. Pfizer was up 1.7%, outpacing the S&P 500 Index‘s (INDEXSP: .INX) 0.2% gain, and BioNTech had leaped ahead by 4.5%.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

More reading

• Here are the US shares that CommSec customers are buying
• Warren Buffett bought 4 pharma giants in Q3
• Dow Jones hits new record highs. Are ASX 200 shares next?
• 3 shares that have strongly outperformed their sectors this month
• ASX 200 Weekly Wrap: ASX continues to hit post-COVID highs

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post New data shows higher efficacy rate for Pfizer and BioNTech coronavirus vaccine candidate appeared first on Motley Fool Australia.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

from Motley Fool Australia https://ift.tt/3kJRIK2

The IPH Ltd (ASX: IPH) share price has edged higher in morning trading after the intellectual property (IP) services provider advised its earnings have grown in the first four months of FY21, predominantly due to synergies arising from the acquisition of Xenith Group. At the time of writing, the IPH share price has risen by 0.86% to $7.03.

What’s moving the IPH share price?

The IPH share price is inching higher following the company’s annual general meeting (AGM) this morning. In his address to shareholders, IPH Chief Executive, Dr Andrew Blattman, advised that the company delivered a solid result in FY20, despite the COVID-19 pandemic. 

He reported that IPH delivered these impressive metrics in FY20:

• Earnings before interest, tax, depreciation and amortisation (EBITDA) was $126 million compared to $89.7 million for the prior year.
• Underlying revenue for the year increased by 44% to $370 million.
• Underlying net profit after tax (NPAT) lifted by 24% to $78 million.

Blattman also praised his team for the successful integration of Xenith into the IPH group. Xenith was acquired in 2019, in what was the largest acquisition in IPH’s history since its listing in 2014. The company now says that it has successfully delivered net cost synergies of $3.5 million, which is in line with the guidance the company provided at the time of the acquisition.

Update on FY21 trading

In what has been a challenging economic climate for many businesses due to the global pandemic, IPH’s first four months of trading has resulted in ‘like-for-like’ EBITDA growth against the prior corresponding period. IPH says that this growth has been predominately driven by the synergies generated from the acquisition of Xenith.

Having said that, IPH advised it continues to operate in difficult market conditions, as Australian patent filings decreased by 1% in the four months to October. In total, IPH filings (excluding Innovation Patents) declined 8.1% during this period.

Blatmann said:

While we have not had any significant client losses over this period, we are seeing some large clients who are filing less at this time. Additionally, we have the local market’s largest exposure to US clients, which as you would expect, has experienced some short-term disruption due to COVID.

How is the IPH share price performing in 2020?

IPH is a major IP company that provides services including the protection, commercialisation, enforcement, and management of intellectual property. The IPH share price has more than tripled since its initial public offering (IPO) to become the leading IP services firm in the Asia Pacific region.

However, the IPH share price has been volatile this year. It started the year at $8.20, before surging to $10.22 in February. It then dropped to $6.26 at the height of the pandemic in March, before arriving at today’s price of $7.03. All in all, the IPH share price has dropped by around 14% on a year-to-date basis. IPH commands a market capitalisation of $1.5 billion at this price.

More reading

• Why ALS, BlueScope, FlexiGroup, & Perpetual shares are charging higher
• Can Magellan (ASX:MFG) prosper in a market dominated by Macquarie (ASX:MQG)?
• Why the BlueScope (ASX:BSL) share price is surging 6%
• Here’s why the 5G Networks (ASX:5GN) share price is zooming higher
• IAG (ASX:IAG) shares halt trading after court rules COVID-19 claims valid

Eddy Sunarto has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. recommends IPH Ltd. The Motley Fool Australia has recommended IPH Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post The IPH (ASX:IPH) share price is gaining ground. Here’s why appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/35HFI7n

In late morning trade on Thursday the S&P/ASX 200 Index (ASX: XJO) has followed the lead of U.S. markets and looks set to end its winning streak. The benchmark index is currently down 0.4% to 6,505.2 points.

Four shares that are not letting that hold them back are listed below. Here’s why they are charging higher:

ALS Ltd (ASX: ALQ)

The ALS share price is up 8% to $10.23 a day after the release of its half year results. The catalyst for this appears to have been a positive reaction to its results from a number of brokers. One that was particularly positive was Macquarie. In response to the release, the broker has retained its outperform rating and lifted the price target on its shares to $10.65.

BlueScope Steel Limited (ASX: BSL)

The BlueScope share price has stormed 5.5% higher to $17.78. This follows the release of its updated guidance for the first half of FY 2021. According to the release, underlying earnings before interest and tax (EBIT) is expected to be approximately $475 million for the half. This includes the contribution made from the recent industrial warehouse property sale. The new guidance represents a rise of 80% over the second half of FY 2020.

FlexiGroup Limited (ASX: FXL)

The FlexiGroup share price has jumped 9% higher to $1.17. Investors have been buying the financial services company’s shares after it announced a deal with Mastercard for its bundll buy now pay anywhere product. In addition to this, the company revealed that it expects its first half cash net profit after tax to be ahead of the $34.5 million it achieved in the prior corresponding period.

Perpetual Limited (ASX: PPT)

The Perpetual share price is up 4% to $31.41. This appears to have been driven by a broker note out of Morgan Stanley. In response to the completion of its acquisition of Barrow Hanley, the broker has retained its overweight rating but trimmed its price target on the fund manager’s shares to $42.50.

More reading

• Why the BlueScope (ASX:BSL) share price is surging 6%
• FlexiGroup (ASX:FXL) share price surges 10% higher on Mastercard deal and trading update
• Why a2 Milk, ALS, Centuria Industrial, & Serko shares are dropping lower
• Why the Downer (ASX:DOW) share price is outperforming today
• Why the ALS (ASX:ALQ) share price sank 4% lower today

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has recommended FlexiGroup Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Why ALS, BlueScope, FlexiGroup, & Perpetual shares are charging higher appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/3fge3hk

The Magellan Financial Group Ltd (ASX: MFG) share price has been flat after announcing a 40% stake in new investment bank, Barrenjoey. Regardless, the company has managed to secure some top flight talent to run the fledgling investment bank.

This includes outgoing chairman of Australia and New Zealand Banking GrpLtd (ASX: ANZ), David Gonski. He has been appointed as the independent chairman of the new investment bank.

Magellan has also secured many top investment bank deal makers of UBS Group AG (SWX: UBSG) in Australia, and can boast ex-CEO of BHP Group Ltd (ASX: BHP) Ken McKenzie as a strategic advisor.

But despite Magellan’s moving and shaking, the financial news has been filled with the investment banking activity of Macquarie Group Ltd (ASX: MQG). Furthermore, the Macquarie share price has risen steadily by 5% over the past month.

Investment banks act as intermediaries between companies and capital markets. For example, companies could engage an investment banker for assistance with an initial public offering (IPO), a capital raising, or a refinancing strategy. 

What’s fueling the Macquarie share price?

In recent weeks, Macquarie Capital has been named a key player in many major ASX events. For instance, just last week the Australian Financial Review disclosed that Macquarie had secured an IPO funding pipeline for local services marketplace, Air Tasker. Moreover, the investment bank is running the Nuix IPO, likely to be either the largest or second largest IPO this year.

Nuix has developed technology that extracts meaningful information from unstructured data. It finalised IPO details last week, settling on a listing worth $975.3 million. When combined with the shares the company owns, it values the company at $1.8117 billion.

Other companies seeking to float in the near future include legal company HWL Ebsworth, with an estimated value of $917 million; Fantastic Furniture, planning to raise up to $669 million; and Sapura Energy, which is potentially a US$2 billion float.  

The Magellan-backed challenger

Magellan holds a 40% stake, and a 4.99% voting interest, in new investment bank and full-service brokerage, Barrenjoey. The bank plans to provide corporate and strategic advisory services, equity and debt capital market underwritings, cash equites, research, prime brokerage and fixed income trading. However, Magellan’s investment in Barrenjoey has received mixed reviews. In fact, the Magellan share price fell 5% on the day of the announcement.

As a rule of thumb metric, investment banks are often valued at 1 to 1.5 times revenue . Given that Magellan has paid $155 million for 40% of Barrenjoey, the full valuation would be just under $400 million. Meaning, the start-up bank has to be earning $400 to $600 million to justify this price.

Foolish takeaway

Macquarie Capital is regularly among the top three investment banks nationally every year. Something that is reflected in its ASX share price.

With the current pipeline of IPOs under way, it may repeat that again this year. However, despite being a start-up in a competitive sector, Barrenjoey has plenty of talent at the helm.

More reading

• 3 ASX dividend shares with large and growing dividends
• Morgan Stanley updates its share price targets for the big 4 banks
• Analysts name 2 of the best ASX shares to buy now
• Macquarie (ASX:MQG) picks best ASX stocks to buy for 2021 post-COVID recovery
• Aussie companies blast ‘knee-jerk’ COVID-19 border closures

Motley Fool contributor Daryl Mather has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Macquarie Group Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Can Magellan (ASX:MFG) prosper in a market dominated by Macquarie (ASX:MQG)? appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/3feAmnt

The BlueScope Steel Limited (ASX: BSL) share price is rocketing higher this morning after the company released a trading update. At the time of writing, the BlueScope share price is up 6.0% to $17.83 after reaching a new, multi-year high of $18.24 during the opening minutes of trade.

Upgraded guidance

According to this morning’s release, BlueScope reported strong demand for its steel products. Although most of the heavy lifting came from its Australian segment, BlueScope upgraded its forecasts for the first half of FY21.

Underlying earnings before interest and tax (EBIT) is projected to be around $475 million. BlueScope noted that this includes the contribution made from the industrial warehouse property sale that was executed recently. The new guidance represents a rise of 80% over the second half of FY20.

What are the key drivers for the BlueScope share price?

The BlueScope share price is on the move today after the company advised its Australian segment is on track to deliver a substantially better result than the prior period. BlueScope reported that demand for domestic construction and distribution remains strong, particularly for coated and painted products. Furthermore, export coke levels are expected to be above what was attained at the end of the last financial year.

In the United States, North Star, owned by BlueScope, continues to ship steel at full capacity. A major scheduled maintenance outage was completed in the backdrop. Since the end of the second half of FY20, there has been a significant increase in Midwest hot rolled coil prices and other raw materials costs. BlueScope acknowledged that, as there is a general lag between market price and sales, underlying EBIT for North Star is predicted to be lower than the second half of FY20.

The building products segment in Asia and North America is anticipated to produce a better performance than the last results recorded. In ASEAN (Association of Southeast Asian Nations) alone, EBIT is predicted to be at least double that of the second half of FY20. The North America business is matching current estimates similar to the prior period.

Moving to the Buildings North America division, the engineering business has been growing consistently. This was supported by the $40 million property sale conducted earlier this month.

New Zealand and Pacific Island’s performance has been gaining traction in the second-half due to operations resuming post COVID-19. The company stated that it is still continuing to implement a restructure of the business. Depreciation and amortisation is expected to be roughly $15 million to $20 million lower compared to the second half of FY20.

What did management say?

BlueScope managing director and CEO, Mr Mark Vassella, commented on the performance achieved so far. He said:

All operating segments are performing well and momentum has continued to build as we approach the end of 1H FY2021. Residential alterations and additions activity, demand for detached new housing, and growth in demand for e-commerce warehouse and logistics facilities are all robust and US automotive industry demand is recovering strongly.

Demand strength, particularly in the Australian market, has continued to outpace our expectations. We now expect that Australian construction and manufacturing activity will remain strong, driving elevated domestic steel despatches for the balance of 1H FY2021.

Benchmark steel spreads in East Asia and the Midwest US are currently above longer-term averages as the beginning of 2H FY2021 approaches. Nonetheless there remains uncertainty around spreads and volumes given the risks of the evolving impact of COVID-19 which could disrupt demand, supply chains and operations, and broader macroeconomic activity.

BlueScope share price summary

The BlueScope share price is making a stunning comeback since falling to as low as $8.03 in March. Shares in the steel making company reached a new multi-year high yesterday of $17.26 before surging again to a fresh high following today’s release.

Based on the current BlueScope share price, the company has a market capitalisation of $8.5 billion and a price-to-earnings (P/E) ratio of 89.

More reading

• Top fundie, Wilson, names ASX shares to buy
• Why these 7 ASX 200 shares received broker upgrades this week
• ASX 200 Weekly Wrap: ASX snaps winning streak… just
• These were the best performing ASX 200 shares last week
• The ASX 200 was mixed today, it finished down 0.1%

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Why the BlueScope (ASX:BSL) share price is surging 6% appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/3fdK2hW

The 5G Networks Ltd (ASX: 5GN) share price is charging higher on Thursday after announcing a new acquisition.

At the time of writing, the data network provider’s shares are up 4% to $1.63.

What did 5G Networks announce?

This morning 5G Networks announced that it has entered into a lease agreement for the ex-Pipe Networks Data Centre in Fortitude Valley.

According to the release, the company has agreed an all-cash consideration of $1.1 million, which includes all operating infrastructure at the facility.

Management advised that the acquisition will be funded from existing cash reserves, with a generous rent-free period on a 10-year lease.

It expects the facility to be operational January 2021, with the inclusion of the latest power redundancy equipment and cooling systems. Management notes that the data centre has the capacity to support 250 racks and access to 3MW of power on dual power grid, which offers the highest level of redundancy.

This acquisition means the company now operates data centres in each state on the east coast of Australia.

Why acquire this data centre?

Management advised that this strategic investment will allow 5GN customers to connect directly to the data centre via 5GN dark fibre once the new rollout is complete.

It notes that cross selling of infrastructure aligns with the company’s focused acquisition and growth strategy. It will also accelerate the continued execution of the 5GN wholesale channel strategy for infrastructure and data centre services.

5G Networks’s Managing Director, Joe Demase, commented: “We are really excited to be exploiting our advantage of being a DC operator and fibre network owner, I haven’t seen rack space and dark fibre product bundling from one provider before, but this is what our customers are asking for. It allows our partners to grow with a fixed cost model which also includes easy migration as a result of our 6-month rack offer.”

That offer will see rental charges waived and a complementary dark fibre cross connect to any data centre in Brisbane.

More reading

• Why 5G Networks, Cedar Woods, SEEK, & Tyro shares tumbled lower today

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. recommends 5G NETWORK FPO. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Here’s why the 5G Networks (ASX:5GN) share price is zooming higher appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/38WXrtx

Trading was suspended on Insurance Australia Group Ltd (ASX: IAG) shares on Thursday morning after a court ruling that could have dire consequences for the insurance giant.

On Wednesday, the New South Wales Court of Appeal ruled that rejecting business interruption insurance claims on the basis of COVID-19 losses is invalid.

The decision was a shock for the industry, which thought that including COVID-19 as a “quarantinable disease” as defined in the now-repealed Quarantine Act would be sufficient to decline claims.

The Insurance Council of Australia (ICA) argued that regardless of wording, the spirit of the policies were meant to exclude pandemics.

QBE Insurance Group Ltd (ASX: QBE), which was also represented by the council in the court case, did not suspend trading of its shares.

The company stated to the ASX that business customers still must jump through other hoops to make a successful claim.

“Notwithstanding the ruling, QBE notes that the particular wording of QBE business interruption policies require a number of policy triggers to be met in order for policyholders to be entitled to indemnity for business interruption.”

Business disruption claims were expected to be capped at $5 million per occurrence, QBE added.

ICA has stated it’s considering an appeal to the High Court.

IAG and QBE have not disclosed how much this decision could impact their bottom line. But Suncorp Group Ltd (ASX: SUN) earlier this week set aside an extra $125 million to cover themselves for COVID-19 claims.

Suncorp stated to the market that, overall, it has $195 million allocated for potential claims.

“While the group continues to review the judgment, the test case outcome is not expected to affect the total business interruption provision.”

Both IAG and QBE shares have climbed more than 12% in the past month. Suncorp has risen about 8%.

The court case specifically referred to a claim made by a business customer to its insurer, HDI. But it acted as a test case for the entire industry since most insurers use similar wording in their policies.

More reading

• Why the Downer (ASX:DOW) share price is outperforming today
• Suncorp (ASX:SUN) share price higher after trading update
• Can the Suncorp (ASX:SUN) share price go higher from here?
• Leading brokers name 3 ASX shares to sell today
• Why the CBA (ASX:CBA) share price and these ASX stocks could get a $100bn boost

Motley Fool contributor Tony Yoo has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post IAG (ASX:IAG) shares halt trading after court rules COVID-19 claims valid appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/2UDm0mW

Agrochemicals company Nufarm Limited (ASX:NUF) today reported a significant year-on-year revenue growth of 23% in the 2 months to the end of September. This growth was driven primarily by stronger sales in Australia and Europe.

At the time of writing, the Nufarm share price is trading up 1.45% at $4.21.

What else did Nufarm announce?

The company’s gross profit increased 9% on prior comparative period, while underlying earnings before interest, tax, depreciation, and ammortisation (EBITDA) was up by 18%.

In terms of geographical results, revenues in Australia and New Zealand increased 37%, with improved weather conditions in Australia driving good demand for herbicides. Meanwhile, revenues in Europe also lifted significantly by 38%. North America was up by just 4% after storms and bushfires impacted sales.

Nufarm says the sales momentum has continued in all regions through October, providing the company with a good to start to FY21. 

What does Nufarm do?

With origins dating back more than 100 years, Nufarm is a global manufacturer of crop protection solutions and seeds. Nufarm’s products are designed to protect commercial crops from a variety of pests, weeds, and diseases, thereby maximising crop yields.  It first listed on the ASX in 1988. 

Nufarm share price performance this year

The Nufarm share price has lost almost 30% in 2020. The company recorded a statutory net loss after tax of $362 million. This was attributed to weak seasonal conditions faced in the first 6 months and the effects of COVID-19. The company has continued to suspend all dividends until further notice.  The board said it would revisit this decision in future based on the prevailing market conditions.

More reading

• RCEP trade deal boosts Australian exporter share prices
• Latest 3 “buy” recommendations from top brokers
• Buy these 3 ASX stocks that hit a 52-week low during this market meltdown

Motley Fool contributor Eddy Sunarto has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Why the Nufarm (ASX:NUF) share price is up this morning appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/3kMQwFE

Oil producer Oil Search Limited (ASX: OSH) today announced a significant 33% increase in contingent resources in its Pikka oil field in Alaska. This takes its total gross Alaskan North Slope 2C resources within Oil Search’s portfolio from 728 million barrels of oil to 968 million barrels of oil, a 93% increase from its original estimate in 2018. 

The Oil Search share price is down by 2.36% at the open of trade today to $3.73 amidst a broader fall in the ASX.

More details on the find

Oil Search told an investor conference this morning that the Pikka project was now well positioned for its Phase-1 single drill site in early 2021. The development will use a capital efficient approach that will deliver a breakeven cost of less than US$40/barrel, with gross capital costs of under US$3 billion.

Production from Phase-1 will support the funding for Phase-2, which will comprise the full field development incorporating two additional well pads. It expects first oil from this project in 2025.

Other news from the briefing

Oil Search said the COVID-19 pandemic had helped the company become more resilient as it made efforts to reduce its cost base.

Speaking at the conference this morning, Oil Search managing director Dr Keiran Wulff told investors:

The challenges posed by the pandemic and oil price downturn, combined with global trends and societal expectations, have been the catalyst for us to review our past performance and make sustained improvements to position Oil Search for long term success.

Mr Wulff said the company strategy included three disciplined phases: driving sustained low costs of its PNG operations, commercialising the Pikka development at a breakeven cost of less than US$40/bbl, and considering targeted complementary energy investments.

About the Oil Search share price in 2020

The Oil Search share price is a top performer over the past month, beating the overall energy sector’s performance on the back of coronavirus vaccine news. However, like all energy producers, it has not had a year to remember. In October, the company delivered disappointing third-quarter results, and said that it did not expect LNG demand to fully recover until 2027.

The Oil Search share price has lost 45% of its value this year. At today’s price of $3.73, it commands a market cap of $7.7 billion.

More reading

• Why Douugh, Mirvac, Oil Search, & Westpac shares are charging higher
• 3 shares that have strongly outperformed their sectors this month
• ASX 200 Weekly Wrap: ASX continues to hit post-COVID highs
• These were the best performing ASX 200 shares last week
• ASX 200 surges again on Wednesday

Motley Fool contributor Eddy Sunarto has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post The Oil Search (ASX:OSH) share is lower today despite oil find appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/2UCu0F1

The Starpharma Holdings Limited (ASX: SPL) share price has been a very positive performer on Thursday.

At the time of writing, the dendrimer products developer’s shares are up 6% to $1.40.

Why is the Starpharma share price racing higher?

Investors have been buying Starpharma’s shares today after it released an update on its antiviral nasal spray active (SPL7013).

According to the release, additional testing has been undertaken and shows the potent antiviral activity of SPL7013 against human respiratory syncytial virus (RSV).

RSV is a common and very contagious virus that affects the lungs and airways. It is most problematic in the young and the elderly and those with weakened immune systems, or chronic heart and lung disease, including asthma. It is also one of the viruses responsible for the common cold.

The company notes that more than 177,000 adults are hospitalised and 14,000 of them die each year in the United States due to RSV infection.

Despite its prevalence and extensive efforts by pharmaceutical companies over the years, there are few strategies available to prevent or treat RSV infection. There are no vaccines and few therapeutics available to treat the infection. Furthermore, like influenza, RSV frequently mutates making vaccine development challenging.

This latest data further expands the antiviral spectrum of SPL7013 in respiratory viruses, which already includes SARS-CoV-2 (COVID-19) and H1N1 influenza.

Starpharma is also testing SPL7013 against other respiratory viruses with the intention to add these to the product claims as data becomes available.

Starpharma’s CEO, Dr Jackie Fairley, commented: “We are pleased to announce the expanded use of SPL7013 in RSV. RSV is a common virus which has significant morbidity and mortality for the elderly and those with chronic disease.”

“What these results confirm, is that SPL7013 has broad spectrum antiviral activity, and that VIRALEZE could play an important role for future pandemic preparedness. The rapid development and commercialisation of SPL7013 as VIRALEZE antiviral nasal spray is on track, with the product set to be available in some markets as early as 1H CY2021,” she added.

More reading

• Vocus (ASX:VOC) share price lower on Vocus NZ IPO plans
• FlexiGroup (ASX:FXL) share price surges 10% higher on Mastercard deal and trading update
• Altium (ASX:ALU) share price pushes higher following AGM update
• 2 ASX growth shares predicting big growth this decade
• Why these ASX shares just stormed to 52-week highs

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Starpharma Holdings Limited. The Motley Fool Australia has recommended Starpharma Holdings Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Why the Starpharma (ASX:SPL) share price is racing higher today appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/3nB93qj